Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today reported results for the second quarter of fiscal 2014, which ended March 28, 2014. The company also announced that it revised and increased guidance for fiscal 2014 reflecting the strong performance of the company’s base business and the recently completed acquisition of Cadence Pharmaceuticals.
Help employers find you! Check out all the jobs and post your resume.
